| HOME >> MEDICINE >> TECHNOLOGY |
(1.0)20.1(3.0)48.6Restructuring & other special items
44.68.7125.548.5Adjusted total operating expenses
$
436.1$
368.4$
,676.5$
,460.8Adjusted earnings from operations (b)
$
409.3$
363.8$
,688.6$
,475.7Three Months EndedYear EndedDecember 31,December 31,2012201120122011GAAP interest expense$
74.6$
81.1$
308.7$
335.9Deduct:Interest expense related to clean energy investment (c)
1.4—6.2—Non-cash accretion of contingent consideration liability
7.7—30.7—Non-cash interest, primarily amortization of convertible debt discount
6.213.029.449.8Adjusted interest expense
$
59.3$
8.1$
242.4$
286.1Three Months EndedYear EndedDecember 31,December 31,2012201120122011GAAP other income (expense)$
2.8$
(37.4)$
3.4$
(14.9)Add (Deduct):Clean energy investment operating results (c)
4.4—16.8—Financing related costs
—34.0—$
34.0Restructuring & other special items
(1.7)1.4(0.7)$
.2Adjusted other income (expense)
$
5.5$
(2.0)$
9.5$
9.3Reconciliation of cash provided by operating activitiesYear Ended December 31,20122011GAAP cash provided by operating activities$
949$
720Add:Payment of litigation settlements
10981Payment of interest rate swap settlement
—14Adjustments for timing of cash receipts deducted in prior periods
627Payment to Merck KGaA related to income tax benefits on indemnified litigation
—60Increase in deferred revenue
18—Income tax items
(14)—Adjusted cash provided by operating activities
$
,124$
882(a)
Adjusted gross profit is calculated as total revenues less adjusted cost of sales. Adjusted gross margin is calculated as adjusted gross profit divided by total revenue.
'/>"/>
| SOURCE Mylan Inc. Copyright©2012 PR Newswire. All rights reserved |